Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

AimSelexipag is an oral selective prostacyclin receptor agonist approved for treatment of patients with pulmonary arterial hypertension (PAH). In the present study, we aim to assess the safety and efficacy of selexipag in triple combination therapy with endothelial receptor antagonists (ERAs) and PD...

Full description

Bibliographic Details
Main Authors: Xiaopei Cui, Weida Lu, Deyuan Zhang, Liangyi Qie, Haijun Li, Xiao Li, Hui Liu, Qiushang Ji
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
pulmonary arterial hypertension
triple combination
selexipag
tolerability
risk assessment
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.991586/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.991586/full

Similar Items